The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Approaching treatment decisions for elderly patients with DLBCL who fall between “fit” and “frail”
In this video, Lorenz Thurner, MD, Saarland University Medical Center, Homburg, Germany, comments on the treatment decisions for elderly patients with diffuse large B-cell lymphoma (DLBCL) who fall between “fit” and “frail”, emphasizing the importance of a personalized approach that takes into account the patient’s geriatric status and biology. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s an interesting question. It’s always very important to see the patient yourself and talk to him. It’s not just a decision based on a tumor conference. There are the geriatric scores which should be implemented. However, it’s a challenge to implement them in the daily workload. But this gives important advice on how these patients should be treated. I think the elderly DLBCL have a different biology, so there are trials ongoing...
That’s an interesting question. It’s always very important to see the patient yourself and talk to him. It’s not just a decision based on a tumor conference. There are the geriatric scores which should be implemented. However, it’s a challenge to implement them in the daily workload. But this gives important advice on how these patients should be treated. I think the elderly DLBCL have a different biology, so there are trials ongoing. I think it’s very important to include these patients into trials because of the different biology and for instance we expect that they show a much better activity to BTK inhibitors. So yeah, I think geriatric assessment is important and for patients over 75 it should be really well evaluated if a full dose of CHOP is given or not.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
